Journal of Cancer Epidemiology and Prevention Open Access

  • Journal h-index: 11
  • Journal CiteScore: 0.73
  • Journal Impact Factor: 0.49
  • Average acceptance to publication time (5-7 days)
  • Average article processing time (30-45 days) Less than 5 volumes 30 days
    8 - 9 volumes 40 days
    10 and more volumes 45 days
Reach us +32 25889658

Dr. Rafie Hamidpour

Dr. Rafie Hamidpour
Editor-in-Chief
Pars Bioscience Research Center
Leawood, Kansas, USA

Biography

Dr. Rafie Hamidpour is president and CEO at the Pars Bioscience Research center and the director of the Herbal Medicine Laboratory at this institute. He is a traditional cancer scientist focusing on intervention with Traditional medicinal and pharmacology of herbal medicine in order to treat human tumor that invades surrounding tissue and may spread to distant parts of the body by way of the lymphatic or circulatory system. Therapeutic targets which are identified to be Cancer-Specific will be pursued by both gene and drug therapy methods by Dr. Hamidpours team towards designing a comprehensive genetics the process by which information in messenger RNA directs the sequence of amino acids assembled by a ribosome during protein synthesis Transcriptional targeting of an oncolytic virus is a virus that preferentially infects and kills cancer cells as the infected cancer cells are destroyed by lysis Viruses is a major focus of research, as the most important pro-oncogenic signaling pathway involved in genetics the first step in the replication of a retrovirus following its infection of a living cell, in which its genetic code is transferred from RNA to a molecule of DNA.
Dr. Rafie Hamidpour has published twelve (12) Books, seven (7) patents and more than 48 papers in reputed journals and has been serving as an editorial board member of reviewer for Journal of Traditional and complementary Medicine, editorial board of head and neck cancer research Journal and editorial board of Medwin Journal.

Research Interest

Cancer-Specific therapeutic targets, Gene therapy for cancer